Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Total Non-Current Liabilities data on record, last reported at $704.7 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 140.97% year-over-year to $704.7 million; the TTM value through Dec 2025 reached $704.7 million, up 140.97%, while the annual FY2025 figure was $704.7 million, 140.97% up from the prior year.
  • Total Non-Current Liabilities reached $704.7 million in Q4 2025 per RVMD's latest filing, up from $652.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $704.7 million in Q4 2025 and bottomed at $87.6 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $231.5 million, with a median of $144.9 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 8.31% in 2023, then soared 234.55% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $134.8 million in 2021, then dropped by 6.19% to $126.4 million in 2022, then surged by 81.11% to $229.0 million in 2023, then grew by 27.7% to $292.4 million in 2024, then surged by 140.97% to $704.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $704.7 million in Q4 2025, $652.5 million in Q3 2025, and $557.0 million in Q2 2025.